KEY FINDINGS The global IBS-C drug market is forecasted to grow at a CAGR of 6.95% between the years 2017 – 2025. Some of the primary factors responsible for the growth in this market are the ease of availability of effective drugs in the market, modern dietary habits affecting the health, various psychological factors leading to irritable bowel syndrome and the potential use of the improved and efficient drugs that are currently in the pipelines.
MARKET INSIGHTS The global IBS-C drug market is segmented according to the type of drug and prescription. The Drugs type is further classified into Linaclotide, Lubiprostone, Osmotic Laxatives, Stimulant Laxatives, and others. Of these, lubiprostone is a highly popular drug in the market. The market by Prescription type is further segmented into prescribed drugs and over the counter drugs. The over the counter drugs are leading this segment as they can be easily bought without any doctor’s prescription.
REGIONAL INSIGHTS The global IBS-C drug market is geographically divided into North America (U.S. & Canada), Europe (Germany, UK, and RoE), Asia Pacific (Japan, China, and RoAPAC) and Rest of the World (Latin America and MENA). Of these, the North America region is anticipated to dominate the global IBS-C drug market over the forecast period on account of its highly developed healthcare systems and advanced medical devices industry.
COMPETITIVE INSIGHTS Some of the major players in the global IBS-C drug market include Nestle, Catalent Pharma Solutions, Abbot Laboratories, Sucampo Pharmaceuticals, Synergy Pharmaceuticals, Novartis, etc.